Clinical Trial Update: EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer [EARLY_Phase 1]

View source ↗

Summary

An early-phase (Phase 1) clinical trial is evaluating the EGF-depleting vaccine CIMAvax-EGF in combination with standard therapy for RAS- and BRAF-wild-type met…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• CIMAvax-EGF (EGF-depleting vaccine CIMAvax-EGF)

Snippet

Sponsor: Roswell Park Cancer Institute | Conditions: Colo-rectal Cancer | EARLY_Phase 1 | Status: ACTIVE_NOT_RECRUITING